Granules India shares in focus after USFDA concludes Hyderabad facility inspection with 11 observations

What happened

The USFDA completed an inspection of Granules India’s finished-dosage facility in Gagillapur, Hyderabad, from October 19 to October 30, 2026, and issued a Form FDA 483 listing 11 observations. The company said none concerned data integrity or cross-contamination, and that manufacturing and distribution were unaffected.

Confirmed

Global impact / market context

The observations concern investigations, change control, qualification of processes and equipment, visual inspections, and documentation. Addressing them may require quality-system work and management attention; if regulators are dissatisfied with the company’s response, future operating conditions could become more difficult, although no current production impact was reported.

Analyst inference

This was the facility’s first USFDA inspection since a February 2025 Warning Letter, following an earlier inspection in 2024. The company says it expects to address the new observations and plans a response within 15 business days, but the article reports no resulting production or distribution disruption.

Confirmed

What to watch

1. Granules said it will submit a comprehensive response to the USFDA within 15 business days; the response and any agency follow-up will indicate whether the observations are resolved. Confirmed
2. The company described corrective and preventive actions, meaning steps to fix problems and stop recurrence, as its route to addressing the observations; implementation may require extra quality work. Confirmed
3. Watch for any later disclosure of manufacturing or distribution changes at Gagillapur, since the company currently reports no impact and further restrictions could affect site output. Analyst inference

Evidence

• Original source link unavailable